TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04022876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-6924
Description: ALRN-6924 administered IV on Days 0-4 prior to topotecan administered IV on Days 1-5 of every 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan administered IV on Days 1-5 of every 21-day cycle.
Study: NCT02401880

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 22 subjects will receive Placebo for 30 days
Study: NCT04291625

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Levator muscle resection
Description: Surgery was performed under general anaesthesia. Two milliliters of 2% lidocaine with 1:100 000 epinephrine is injected subcutaneously. After the upper eyelid incision at the desired crease line, the orbital septum was opened and the preaponeurotic fat was identified and dissected off the levator aponeurosis. The aponeurosis was disinserted from the tarsus, and the complex of levator aponeurosis and Muller muscle was dissected free from the conjunctiva. The desired eyelid height was determined from the proposed formula.~Satisfactory Intraoperative lagophthalmos was defined as a difference of less than 1 mm between recommended by the formula and actual intraoperative lagophthalmos.~After permanent fixation, a caliper was used for precise measurement of lagophthalmos in a supine position. Additional sutures were placed on the medial and lateral sides for satisfactory eyelid contour. The redundant levator complex was excised. Eyelid crease was made by placing three interrupted sutures
Study: NCT02468050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise training
Description: 6 weeks of moderate intensity exercise training (50 - 75% of heart rate reserve). Sessions are facility and home based and include cardiovascular warm-up, cardiovascular training, muscular conditioning, and flexibility exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise training
Description: 6 weeks of moderate intensity exercise training (50 - 75% of heart rate reserve). Sessions are facility and home based and include cardiovascular warm-up, cardiovascular training, muscular conditioning, and flexibility exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Management of exercise
Description: In addition to the 6 week exercise program (refer to Exercise Treatment Group), participants randomly assigned to the Self Management Group will learn strategies for the self management of exercise.
Study: NCT02660905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF;
Description: Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir-Sofosbuvir
Description: Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
Study: NCT02115620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Daily updates on symptoms, weight, vital signs, and relevant labs will be communicated by phone with cardiology nurses at Providence Heart Clinic. Concerning changes in symptoms or signs will trigger a telemedicine clinic visit with a HF specialist using remote video/audio, virtual stethoscope technology, and VZ Cloud managed hosting. The consult will include a virtual face-face interview and physical examination between patient and HF clinician using Cisco Yabber Video, Littman e-stethoscope, and Verizon managed hosting. Medication changes, laboratory testing, additional virtual visits, or in-person clinic visits can be arranged as appropriate.
Study: NCT03782766

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Piezocision
Description: Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocision
Description: Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
Study: NCT01193361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: Tablets, Oral, 75 mg, twice daily, 4-48 weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: Tablets, Oral, 150 mg, twice daily, 4-48 weeks depending on response
Study: NCT04051502

Intervention type: DRUG
Intervention: Method 1: Indocyanine green dye
Description: Injection 4 mL of ICG dye directly into the fallopian tube (1 or more places is acceptable) only to the side where the adnexal mass is located

Intervention type: DRUG
Intervention: Method 2: Indocyanine green dye
Description: 1mL of ICG injected at each of the four sites: only to the side where the adnexal mass is located~* Dorsal side of the IP ligament~* Ventral side of the IP ligament~* Dorsal side of the utero-ovarian ligament~* Ventral side of the utero-ovarian ligament

Intervention type: DRUG
Intervention: Method 3: Indocyanine green dye
Description: Injection of 2mL of ICG dye into the IP ligament pedicle after the adnexal mass has been removed. Only to the side where the adnexal mass is located
Study: NCT02401880

Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin
Description: 44 subjects will receive Empagliflozin for 60 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: 44 subjects will receive Empagliflozin for 60 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin
Description: 44 subjects will receive Empagliflozin for 60 days
Study: NCT02235142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Study: NCT04357015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous tranexamic acid
Description: The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous carbetocin
Description: The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
Study: NCT04051502

Intervention type: DRUG
Intervention: Method 3: Indocyanine green dye
Description: Injection of 2mL of ICG dye into the IP ligament pedicle before the adnexal mass is removed.
Study: NCT04357015

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
Study: NCT01193361

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, twice daily, 4-48 weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon alfa-2a
Description: Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon alfa-2a
Description: Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peg-interferon alfa-2a
Description: Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response
Study: NCT00697424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SleepStyle 200 Auto Series CPAP Humidifier
Description: The device will record on internal software perceived sleep disordered breathing events. Events will also be scored manually on the polysomnography (PSG. Results will then be compared.
Study: NCT04488406

Intervention type: OTHER
Intervention: No Intervention
Description: Not applicable to these subjects. There is no study-related intervention

Intervention type: OTHER
Intervention: No Intervention
Description: Not applicable to these subjects. There is no study-related intervention
Study: NCT01272245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: 1.25 mg/m2 subcutaneously (SQ) every 12 hours (+/- 3 hours) for 3 days (Days 1-3). Each cycle will be 4-7 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 20 mg subcutaneously every 12 hours (+/- 3 hours) for 7 days (Days 1-7). Each cycle will be 4-7 weeks.
Study: NCT00143039

Intervention type: PROCEDURE
Intervention: Tandem MS test for inborn errors of metabolism
Description: Tandem MS spectrometry test will be done on all maternal blood, amniotic fluid and newborn blood samples for both groups.

Intervention type: PROCEDURE
Intervention: Tandem MS test for inborn errors of metabolism
Description: Tandem MS spectrometry test will be done on all maternal blood, amniotic fluid and newborn blood samples for both groups.
Study: NCT02058186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral vitamin D

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03907085

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HILT + exercise
Description: High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo HILT + exercise
Description: Placebo HILT group; Placebo therapy was applied in five sessions a week for three weeks, with a total of 15 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
Study: NCT01611558

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study: NCT02705339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Standard of care biopsies will be taken at diagnosis and at the time of disease progression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: -Approximately 4 teaspoons of blood will be drawn before treatment begins and at the time of disease progression to look at cell-free DNA
Study: NCT01165268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Once daily, 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Once daily, 7 days
Study: NCT01739192

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: Subjects will be maintained on oral bupropion or placebo during the study.
Study: NCT04195386

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Restoration with Chemically activated Composite resin Alkasite
Description: Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with chemically activated composite resin Alkasite.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Restoration with Resin-Modified Glass ionomer Cement
Description: Selective removal of dental caries with manual instruments, under relative isolation, application of polyacrylic acid and restoration with resin-modified glass ionomer cement.
Study: NCT04039152

Intervention type: OTHER
Intervention: locally adapted neonatal sepsis treatment protocol
Description: the neonatal sepsis treatment protocol was modified according to the local antibiotics susceptibility patterns
Study: NCT00536952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmozyme
Description: Pulmozyme 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 5 days per week for 4 weeks

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Radiation Therapy
Description: 5 days per week for 4 weeks
Study: NCT03925051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: mAb targeting RANKL. human monoclonal antibody targeting RANKL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB807
Description: human monoclonal antibody targeting RANKL.
Study: NCT00701805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Intravenous (IV) paricalcitol, 3 times weekly, immediately before completion of hemodialysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Intravenous (IV) paricalcitol, 3 times weekly, immediately before completion of hemodialysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Intravenous (IV) paricalcitol, 3 times weekly, immediately before completion of hemodialysis.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Intravenous (IV) paricalcitol, 3 times weekly, immediately before completion of hemodialysis.
Study: NCT01536808

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac RMI
Description: Cardiac RMI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Analysis telomere
Description: Analysis telomere

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress test
Description: Stress test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: echocardiography
Description: echocardiography
Study: NCT00418977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Therapy (Maudsley Method)
Description: The goal of FBT is to resolve the eating disorder and return the patient to healthy psychosocial and physiological development through active family involvement across three treatment phases. In Phase I, therapy is focused on the disordered eating. The therapist primarily makes careful, persistent requests for united parental action toward re-feeding and/or regulating eating habits and directs the discussion so as to create and reinforce a strong parental alliance around their efforts at feeding their child. In Phase II, the goal is to gradually transfer control over eating back to the participant, with the parents still maintaining general oversight and responsibility for continued progression toward healthy habits. In Phase III, the central goal is establishment of a healthy child or adolescent relationship with the parents where disordered eating is not the basis of interaction.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Supportive Psychotherapy
Description: The goal of ISP is for the patient to understand and address the psychological issues underlying the origin and maintenance of the eating disorder. This work is done directly with the child/adolescent. In this treatment, eating disorders are seen as complicated (e.g., they tend to mask other underlying difficulties). In Phase I, the aims are to establish a sound therapeutic relationship, obtain a comprehensive description of the eating problem and its development, identify underlying problems that might be responsible for the disordered eating, and inform the patient about the dangers of eating disorders. Phase II encourages participants to explore underlying emotional problems, facilitates self-disclosure and expression of feelings, and fosters independence. Phase III focuses on how other underlying issues might affect future adjustment.
Study: NCT05035433

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First lithotripsy and then EPBD
Description: After successful selective bile duct intubation, contrast agent was injected to measure the thickness of the bile duct and the size of bile duct stones under fluoroscopy. For those meeting the inclusion criteria, sphincterotomy was performed first.Papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken line to suitable size after the switch to expanding balloon EPBD and further kidney stones, papillary sphincter incision after indwelling godet in bile duct, anti-popular character silk will be crushed stone on top into rubble after biliary tract, broken balloon to suitable size after the switch to expansion, expansion size 10-12 mm, according to the lower bile duct diameter, expansion time of 30 seconds.Then, the stones were removed with a net basket or balloon, and the nasobiliary duct was placed to end the operation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First EPBD and then lithotripsy
Description: After puncture of the papillary sphincter, the guide wire was indwelled in the bile duct, and the columnar dilating balloon was inserted in exchange. The dilation size was 10-12mm, and the dilation time was 30 seconds according to the diameter of the lower end of the bile duct.At the end of the expansion, the stones were broken to a suitable size using a one-piece gravel net basket.The calculi were removed by using a stone net basket or balloon, and the nasobiliary duct was placed to end the operation.
Study: NCT01956370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex™ device for adult male circumcision
Description: The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical circumcision
Description: The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
Study: NCT00741039

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated influenza vaccine and the 23- valent pneumococcal vaccine
Description: Patients \>65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23-valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured, as will serum IgG levels and IgG subtypes. At 8-16 weeks after vaccination, post vaccine titers, CBC, lymphoid phenotype and function will be assessed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)
Description: MSKCC employee volunteer controls \> or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly)and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured. At approximately 8-16 weeks after vaccination, post vaccine titers will be measured again.
Study: NCT00817115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Region-of-Interest Imaging (X-ray Fovea Imaging)
Description: Use of an experimental fluoroscopy system fitted with a region-of-interest attenuator (fovea) to evaluate or treat lesions during cardiac interventional procedures.
Study: NCT02344030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: channeled blade
Description: In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: channeled blade
Description: In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard blade
Description: In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard blade
Description: In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
Study: NCT01563718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naltrexone for extended release injectable suspension
Description: VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone for extended release injectable suspension
Description: VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.